Dynamics of polyclonal immuno-reconstitution after allogeneic transplant with post-transplant cyclophosphamide and letermovir-Reference-Cited by-同舟云学术

Dynamics of polyclonal immuno-reconstitution after allogeneic transplant with post-transplant cyclophosphamide and letermovir

Published:2023-07-19 Issue: Volume: Page:
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Orofino Giorgio,Xue Elisabetta,Doglio Matteo,Noviello Maddalena,Tassi Elena,Cristante Matteo,Acerbis Andrea,Clerici Daniela,Farina Francesca^ORCID,Campodonico Edoardo,Bruno Alessandro,Piemontese Simona^ORCID,Mastaglio Sara^ORCID,Diral Elisa,Milani Raffaella^ORCID,Ruggeri Annalisa,Corti Consuelo,Vago Luca^ORCID,Bonini Chiara^ORCID,Peccatori Jacopo,Ciceri Fabio^ORCID,Lupo Stanghellini Maria Teresa^ORCID,Greco Raffaella^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-023-02046-9.pdf

Reference57 articles.

1. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641–50.

2. Kanakry CG, Tsai HL, Bolanos-Meade J, Smith BD, Gojo I, Kanakry JA, et al. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014;124:3817–27.

3. Holtick U, Chemnitz JM, Shimabukuro-Vornhagen A, Theurich S, Chakupurakal G, Krause A, et al. OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation. Eur J Haematol. 2016;96:27–35.

4. Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, et al. Phase II trial of graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide after reduced-intensity busulfan/fludarabine conditioning for hematological malignancies. Biol Blood Marrow Transpl. 2015;21:906–12.

5. Bradstock KF, Bilmon I, Kwan J, Micklethwaite K, Blyth E, Deren S, et al. Single-agent high-dose cyclophosphamide for graft-versus-host disease prophylaxis in human leukocyte antigen-matched reduced-intensity peripheral blood stem cell transplantation results in an unacceptably high rate of severe acute graft-versus-host disease. Biol Blood Marrow Transpl. 2015;21:941–4.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy;Best Practice & Research Clinical Haematology;2024-09

2. Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical peripheral blood stem cell transplants: a large sample, long-term follow-up retrospective study;Frontiers in Immunology;2023-10-26

3. A new direction for cytomegalovirus prophylaxis among transplant recipients: Benefits and nonviral outcomes of letermovir use as primary CMV prophylaxis;Current Opinion in Infectious Diseases;2023-09-29